Biomedical Engineering Reference
In-Depth Information
Narayanan S, Manchanda P, Chintagunta PK (2005) Temporal differences in the role of marketing
communication in new product categories. J Mark Res 42(3):278-290
Neslin SA (2001) ROI analysis of pharmaceutical promotion (RAPP): an independent study.
Presentation to the Association of Medical Publications
OECD (2011) OECD health data 2011—frequently requested data.
http://www.oecd.org/documen
t/16/0,3343,en_2649_34631_2085200_1_1_1_1,00.html
. Accessed 13 July 2011
Osinga EC, Leefl ang PSH, Wieringa JE (2010) Early marketing matters: a time-varying parameter
approach to persistence modeling. J Mark Res 47(1):173-185
Osinga EC, Leefl ang PSH, Wieringa JE (2011) How generic drugs affect brands before and after
entry. Working paper, Tilburg University
Parsons LJ, Vanden Abeele P (1981) Analysis of sales call effectiveness. J Mark Res 18(1):
107-113
Pauwels K, Hanssens DM (2007) Performance regimes and marketing policy shifts. Mark Sci
26(3):293-311
Peres R, Muller E, Mahajan V (2010) Innovation diffusion and new product growth models: a criti-
cal review and research directions. Int J Res Mark 27(2):91-106
Rao AG, Yamada M (1988) Forecasting with a repeat purchase diffusion-model. Manag Sci
34(6):734-752
Rizzo JA (1999) Advertising and competition in the ethical pharmaceutical industry: the case of
antihypertensive drugs. J Law Econ 42(1):89-116
Roberts JH, Lattin JM (2000) Disaggregated-level diffusion models. In: Mahajan V, Muller E,
Wind Y (eds) New-product diffusion models. Kluwer Academic Publishers, Dordrecht, pp
207-236
Rosenthal MB, Berndt ER, Donohue JM, Epstein AM, Frank RG (2003) Demand effects of recent
changes in prescription drug promotion. Front Health Policy Res 6(1):1-27
Ruiz-Conde E, Wieringa JE, Leefl ang PSH (2011) Longitudinal and cross-sectional effects of
marketing instruments on diffusion of pharmaceuticals. Working paper, University of
Groningen
Shankar V (1997) Pioneers' marketing mix reactions to entry in different competitive game
structures: theoretical analysis and empirical illustration. Mark Sci 16(3):271-293
Shankar V (2009) Marketing expenditures over the product life cycle: asymmetries between domi-
nant and weak brands. Working paper, Mays Business School, Texas A&M University
Shankar V, Carpenter GS, Krishnamurthi L (1998) Late mover advantage: how innovative late
entrants outsell pioneers. J Mark Res 35(1):54-70
Shankar V, Carpenter GS, Krishnamurthi L (1999) The advantages of entry in the growth stage of
the product life cycle: an empirical analysis. J Mark Res 36(2):269-276
Shankar V, Carpenter GS, Krishnamurthi L (2008) Strategic marketing decision models for the
pharmaceutical industry. In: Wierenga B (ed) Handbook of marketing decision models.
Springer, New York, pp 469-498
Shugan SM (2004) Endogeneity in marketing decision models. Mark Sci 23(1):1-3
Sood A, James GM, Tellis GJ (2009) Functional regression: a new model for predicting market
penetration of new products. Mark Sci 28(1):36-51
Spurling GK, Mansfi eld PR, Montgomery BD, Lexchin J, Doust J, Othman N, Vitry AI (2010)
Information from pharmaceutical companies and the quality, quantity, and cost of physicians'
prescribing: a systematic review. PLoS Med 7(10):e1000352
Stremersch S (2008) Health and marketing: the emergence of a new fi eld of research. Int J Res
Mark 25(4):229-233
Stremersch S, Lemmens A (2009) Sales growth of new pharmaceuticals across the globe: the role
of regulatory prices. Mark Sci 28(4):690-708
Stremersch S, Van Dyck W (2009) Marketing of the life sciences: a new framework and research
agenda for a nascent fi eld. J Mark 73(4):4-30
Sultan F, Farley JU, Lehmann DR (1990) A meta-analysis of applications of diffusion models.
J Mark Res 27(1):375-388
Search WWH ::
Custom Search